UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn’s Disease: 4 Years of Global Post-marketing Data

Journal of Crohn's and colitis, 2020-02, Vol.14 (2), p.192-204

2020

Volltextzugriff (PDF)

The incidence of and mortality from leukaemias in the UK: a general population-based study

BMC cancer, 2009-07, Vol.9 (1), p.252-252, Article 252

2009

Volltextzugriff (PDF)

Bone marrow transplantation in AML, and socioeconomic class: a UK population-based cohort study

BMC cancer, 2010-09, Vol.10 (1), p.514-514, Article 514

2010

Volltextzugriff (PDF)

Post-marketing Safety Experience with Vedolizumab: Malignancy: 693

The American journal of gastroenterology, 2016-10, Vol.111, p.S313-S314

2016

Volltextzugriff (PDF)

Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post‐marketing data

Alimentary pharmacology & therapeutics, 2020-01, Vol.51 (1), p.149-157

2020

Volltextzugriff (PDF)

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn's Disease Treated With Vedolizumab?

Inflammatory bowel diseases, 2018-04, Vol.24 (5), p.953-959

2018

Volltextzugriff (PDF)

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting

Inflammatory bowel diseases, 2018-10, Vol.24 (11), p.2431-2441

2018

Volltextzugriff (PDF)

Su1876 - Post-Marketing Experience of Vedolizumab in Inflammatory Bowel Disease: Analysis of Pneumonia and Other Respiratory Tract Infections

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S580-S580

2017

Volltextzugriff (PDF)

P014 The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of post-marketing data

The American journal of gastroenterology, 2019-07, Vol.114 (1), p.S4-S4

2019

Volltextzugriff (PDF)

Mo1891 – Post-Marketing Safety Experience of Vedolizumab in Patients Receiving Concomitant Treatment with Other Biologics

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-876-S-876

2019

Volltextzugriff (PDF)

Post-marketing Safety Experience with Vedolizumab: Skin Reactions (Psoriasiform and Eczematous): 691

The American journal of gastroenterology, 2016-10, Vol.111, p.S313

2016

Volltextzugriff (PDF)

Tu1704 - Lower Incidence of Herpes Zoster in Vedolizumab-Treated vs Tofacitinib-Treated Patients with Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-994-S-994

2018

Volltextzugriff (PDF)

Post-Marketing Experience of Vedolizumab in Inflammatory Bowel Disease: Analysis of Pneumonia and Other Respiratory Tract Infections

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S580-S580

2017

Volltextzugriff (PDF)

Su1835 – Vedolizumab Use is Not Associated with Increased Malignancy Incidence: Gemini Long-Term Safety Study Results and Post-Marketing Data

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-628-S-628

2019

Volltextzugriff (PDF)

Sa1699 - Safety of Vedolizumab in Patients Naïve to Treatment with TNF Antagonists Compared with Patients with Prior use of TNF Antagonists

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-360-S-361

2018

Volltextzugriff (PDF)

Sa1703 - Post-Marketing Safety Experience of Vedolizumab in Older Patients with Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-362-S-362

2018

Volltextzugriff (PDF)

Post-Marketing Safety Experience of Vedolizumab in Patients With Pre-existing Viral Hepatitis: 712

The American journal of gastroenterology, 2017-10, Vol.112, p.S393

2017

Volltextzugriff (PDF)

Vedolizumab use in patients with inflammatory bowel diseases undergoing surgery: clinical trials and post-marketing experience

Gastroenterology report, 2019-10, Vol.7 (5), p.322-330

2019

Volltextzugriff (PDF)

Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials

Journal of Crohn's and colitis, 2019-01, Vol.13 (1), p.50-57

2019

Volltextzugriff (PDF)

Su1865 - Vedolizumab Clinical and Post-Marketing Safety Experience of Opportunistic Infections

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S575-S576

2017

Volltextzugriff (PDF)

Vedolizumab Clinical and Post-Marketing Safety Experience of Opportunistic Infections

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S575-S576

2017

Volltextzugriff (PDF)

Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials

Journal of Crohn's and colitis, 2018-07, Vol.12 (8), p.905-919

2018

Volltextzugriff (PDF)

Su1877 - Incidence of Pneumonia and Other Respiratory Tract Infections with Vedolizumab Treatment for Inflammatory Bowel Disease: Clinical Trial Experience

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S580-S581

2017

Volltextzugriff (PDF)

Incidence of Pneumonia and Other Respiratory Tract Infections with Vedolizumab Treatment for Inflammatory Bowel Disease: Clinical Trial Experience

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S580-S581

2017

Volltextzugriff (PDF)

The epidemiology of leukaemia in the uk

Bhayat, Fatima

2010

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(24)
Dissertationen
(1)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Gastroenterology
(11)
The American Journal Of Gastroenterology
(4)
Journal Of Crohn's And Colitis
(3)
Bmc Cancer
(2)
Inflammatory Bowel Diseases
(2)
Alimentary Pharmacology & Therapeutics
(1)
Gastroenterology Report
(1)

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn’s Disease: 4 Years of Global Post-marketing Data

The incidence of and mortality from leukaemias in the UK: a general population-based study

Bone marrow transplantation in AML, and socioeconomic class: a UK population-based cohort study

Post-marketing Safety Experience with Vedolizumab: Malignancy: 693

Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post‐marketing data

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn's Disease Treated With Vedolizumab?

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting

Su1876 - Post-Marketing Experience of Vedolizumab in Inflammatory Bowel Disease: Analysis of Pneumonia and Other Respiratory Tract Infections

P014 The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of post-marketing data

Mo1891 – Post-Marketing Safety Experience of Vedolizumab in Patients Receiving Concomitant Treatment with Other Biologics

Post-marketing Safety Experience with Vedolizumab: Skin Reactions (Psoriasiform and Eczematous): 691

Tu1704 - Lower Incidence of Herpes Zoster in Vedolizumab-Treated vs Tofacitinib-Treated Patients with Ulcerative Colitis

Post-Marketing Experience of Vedolizumab in Inflammatory Bowel Disease: Analysis of Pneumonia and Other Respiratory Tract Infections

Su1835 – Vedolizumab Use is Not Associated with Increased Malignancy Incidence: Gemini Long-Term Safety Study Results and Post-Marketing Data

Sa1699 - Safety of Vedolizumab in Patients Naïve to Treatment with TNF Antagonists Compared with Patients with Prior use of TNF Antagonists

Sa1703 - Post-Marketing Safety Experience of Vedolizumab in Older Patients with Inflammatory Bowel Disease

Post-Marketing Safety Experience of Vedolizumab in Patients With Pre-existing Viral Hepatitis: 712

Vedolizumab use in patients with inflammatory bowel diseases undergoing surgery: clinical trials and post-marketing experience

Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials

Su1865 - Vedolizumab Clinical and Post-Marketing Safety Experience of Opportunistic Infections

Vedolizumab Clinical and Post-Marketing Safety Experience of Opportunistic Infections

Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials

Su1877 - Incidence of Pneumonia and Other Respiratory Tract Infections with Vedolizumab Treatment for Inflammatory Bowel Disease: Clinical Trial Experience

Incidence of Pneumonia and Other Respiratory Tract Infections with Vedolizumab Treatment for Inflammatory Bowel Disease: Clinical Trial Experience

The epidemiology of leukaemia in the uk

Suchergebnisse filtern